Alnylam Pharmaceuticals (NASDAQ:ALNY) Insider Melissa Mclaughlin Sells 2,286 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Melissa Mclaughlin also recently made the following trade(s):

• On Thursday, April 2nd, Melissa Mclaughlin sold 1,624 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $319.59, for a total transaction of $519,014.16.

Alnylam Pharmaceuticals Trading Down 3.3%

Shares of ALNY traded down $10.82 during midday trading on Tuesday, hitting $319.52. The stock had a trading volume of 1,305,095 shares, compared to its average volume of 1,372,175. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The business has a 50-day simple moving average of $326.15 and a two-hundred day simple moving average of $393.92. The firm has a market cap of $42.37 billion, a P/E ratio of 186.85 and a beta of 0.39. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the business earned ($0.65) earnings per share. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ALNY. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Wells Fargo & Company reduced their price target on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $473.87.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $25,000. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $27,000. Finally, Golden State Wealth Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.